Aprea Therapeutics, INC 10-Q quarterly reports

Aprea Therapeutics reports continued net losses and cash burn, with funding expected to last into Q1 2028, while advancing its APR-1051 clinical program.

Aprea Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing financial results, ongoing clinical trials for APR-1051 and ATRN-119, and strategic updates.

Aprea Therapeutics reported significant losses and a dwindling cash balance, raising substantial doubt about its ability to continue as a going concern, despite ongoing clinical development.

Aprea Therapeutics reported a widened year-to-date net loss and a significant cash reduction, raising substantial doubt about its ability to continue as a going concern without additional funding.

Aprea Therapeutics reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern.

Aprea Therapeutics, a clinical-stage biopharmaceutical company, released its third quarter 2024 financial results, highlighting progress in its clinical programs and financial position.

Aprea Therapeutics reports a net loss of $6.3 million for the first half of 2024, while advancing its clinical programs for ATRN-119 and APR-1051.

Aprea Therapeutics' first quarter 2024 results show a net loss of $2.8 million, offset by a $14.7 million boost from a private placement, and progress in clinical trials.